M&A: Cara Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2024-12-18

Corporate Action: Merger

Type: New

Accession Number: 000110465924129596

Comments: On December 17, 2024, Cara Therapeutics, Inc. entered into a significant Merger Agreement with Tvardi Therapeutics, Inc., a company focused on developing therapies for fibrosis-driven diseases. In this deal, Cara's wholly-owned subsidiary, CT Convergence Merger Sub Inc., will merge with Tvardi, resulting in Tvardi becoming a wholly-owned subsidiary of Cara. This strategic move aims to expand Cara's portfolio in the biopharmaceutical sector, targeting novel treatment avenues.

Document Link: View Document